Trust Co. of Virginia VA Has $855,000 Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Trust Co. of Virginia VA cut its position in shares of Becton, Dickinson and Company (NYSE:BDXGet Rating) by 7.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,212 shares of the medical instruments supplier’s stock after selling 266 shares during the quarter. Trust Co. of Virginia VA’s holdings in Becton, Dickinson and were worth $855,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. BlackRock Inc. increased its position in shares of Becton, Dickinson and by 4.2% during the fourth quarter. BlackRock Inc. now owns 20,694,679 shares of the medical instruments supplier’s stock worth $5,204,300,000 after buying an additional 828,789 shares during the period. State Street Corp boosted its stake in Becton, Dickinson and by 3.9% during the fourth quarter. State Street Corp now owns 12,705,205 shares of the medical instruments supplier’s stock worth $3,195,105,000 after acquiring an additional 480,684 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Becton, Dickinson and by 8.3% during the fourth quarter. JPMorgan Chase & Co. now owns 5,048,607 shares of the medical instruments supplier’s stock worth $1,269,624,000 after acquiring an additional 388,758 shares in the last quarter. Geode Capital Management LLC boosted its stake in Becton, Dickinson and by 3.5% during the fourth quarter. Geode Capital Management LLC now owns 4,499,909 shares of the medical instruments supplier’s stock worth $1,128,262,000 after acquiring an additional 150,627 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in Becton, Dickinson and by 19.6% during the fourth quarter. Invesco Ltd. now owns 3,075,333 shares of the medical instruments supplier’s stock worth $773,385,000 after acquiring an additional 504,932 shares in the last quarter. Institutional investors own 86.58% of the company’s stock.

Several brokerages recently issued reports on BDX. StockNews.com lowered shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a research note on Saturday. Piper Sandler cut their target price on shares of Becton, Dickinson and from $265.00 to $255.00 in a research note on Thursday, May 5th. Morgan Stanley raised their price objective on shares of Becton, Dickinson and from $293.00 to $295.00 and gave the company an “overweight” rating in a research note on Monday, April 11th. Finally, Wells Fargo & Company raised shares of Becton, Dickinson and from an “equal weight” rating to an “overweight” rating and set a $275.00 price objective on the stock in a research note on Friday, June 24th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $279.17.

BDX opened at $251.80 on Friday. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.52 and a quick ratio of 1.04. The company’s 50-day moving average is $249.80 and its 200 day moving average is $258.21. Becton, Dickinson and Company has a fifty-two week low of $231.46 and a fifty-two week high of $280.62. The firm has a market capitalization of $71.78 billion, a P/E ratio of 39.72, a PEG ratio of 3.39 and a beta of 0.64.

Becton, Dickinson and (NYSE:BDXGet Rating) last released its quarterly earnings results on Thursday, May 5th. The medical instruments supplier reported $3.18 earnings per share for the quarter, beating analysts’ consensus estimates of $2.98 by $0.20. Becton, Dickinson and had a net margin of 9.59% and a return on equity of 14.91%. The company had revenue of $5.01 billion for the quarter, compared to analyst estimates of $4.78 billion. During the same period last year, the firm earned $3.19 earnings per share. The firm’s revenue was up 2.1% on a year-over-year basis. On average, equities research analysts expect that Becton, Dickinson and Company will post 11.2 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Thursday, June 30th. Investors of record on Thursday, June 9th were given a dividend of $0.87 per share. This represents a $3.48 dividend on an annualized basis and a dividend yield of 1.38%. The ex-dividend date was Wednesday, June 8th. Becton, Dickinson and’s payout ratio is currently 54.89%.

In related news, EVP David Hickey sold 475 shares of the firm’s stock in a transaction dated Friday, May 6th. The shares were sold at an average price of $256.00, for a total transaction of $121,600.00. Following the completion of the sale, the executive vice president now owns 3,806 shares in the company, valued at $974,336. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Thomas J. Spoerel sold 443 shares of Becton, Dickinson and stock in a transaction dated Tuesday, June 7th. The stock was sold at an average price of $260.00, for a total transaction of $115,180.00. Following the completion of the transaction, the vice president now owns 1,058 shares of the company’s stock, valued at approximately $275,080. The disclosure for this sale can be found here. Company insiders own 0.50% of the company’s stock.

Becton, Dickinson and Company Profile (Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Featured Articles

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.